Introduction {#s1}
============

Turner syndrome (TS) represents one of the most common chromosomal anomalies, with a prevalence of about 1:2500-1:3000 live female births ([@DET436C43]). Affected individuals have a variable spectrum of physical and functional alterations likely due to a wide variety of karyotype abnormalities, ranging from 45,X monosomy (50% of cases) to various forms of 45,X/46,XX mosaicism with or without structural defects of the X chromosome in the euploid cell line ([@DET436C39]; [@DET436C43]). Among the clinical features of TS, short stature and ovarian defects are present in almost all cases. Ovarian dysfunction in TS women is likely caused by rapid oocyte-loss in the early stages of the meiotic prophase after the 18th week of fetal life, later resulting in ovarian dysgenesis and streak ovaries and partial or complete absence of pubertal development. Consequently, infertility is one of the main problems for TS women ([@DET436C37]). Studies of the X chromosome breakpoints have revealed the existence of two distinct loci on the Xq (Xq13-q21 and Xq23-q27) and one region on the Xp22.1-p11.2 that are significantly associated with the ovarian phenotype ([@DET436C44]; [@DET436C30]). Different mechanisms to explain the variable phenotypic manifestations of TS include the haploinsufficiency of X-linked genes that escape X chromosome inactivation, such as *SHOX* for short stature ([@DET436C50]; [@DET436C43]), and meiotic-chromosome pairing errors ([@DET436C27]). Nevertheless, spontaneous puberty has been observed in 15--20% of 45,X patients ([@DET436C29]; [@DET436C12]; [@DET436C23]) and in 32% of mosaic patients, inversely correlating with the severity of chromosomal anomalies at conventional karyotype ([@DET436C29]). Consistently, subjects with 45,X frequently have serum follicle-stimulating hormone (FSH) levels already in the post-menopausal range during infancy, whereas FSH levels are generally normal in patients of the same age with mosaic Turner syndrome ([@DET436C9]; [@DET436C2]). Furthermore, a biochemical parameter of ovarian reserve, the antimüllerian hormone is generally low in infants with 45,X or structural abnormalities of the second X, but similar to controls in mosaic Turner patients ([@DET436C16]).

The mechanism supporting pubertal development in a small subset of patients with 45,X is presently unexplained, but low percentage mosaicism, undetected at standard karyotyping, might be a possible explanation. Additionally, submicroscopic copy number variations (CNVs) have recently emerged as an important genetic risk category for premature ovarian insufficiency (POI), both in cases of primary and secondary amenorrhoea. Indeed, in a few cohorts of 46,XX patients diagnosed with POI and analysed by means of high throughput techniques, such as array comparative genomic hybridization (aCGH) and single-nucleotide polymorphism (SNP) array, CNVs affecting several X-linked and autosomal loci with a possible role in female fertility have been detected ([@DET436C1]; [@DET436C8]; [@DET436C19]; [@DET436C34]; [@DET436C20]; [@DET436C24]). Very recently, the SNP array technology has been applied to genotype a large cohort of TS patients, demonstrating the equivalence of this method to metaphase cytogenetics for the diagnosis of TS ([@DET436C33]). However, the potential involvement of CNVs in the modulation of the TS ovarian phenotype has not been investigated.

In this pilot study, we performed new generation genetic (Copy Number Assay) and molecular-cytogenetic (aCGH and iFISH) investigations in a cohort of TS patients in order to better clarify the synergistic burden of X chromosome mosaicism and rare X-linked and autosomal CNVs on the observed ovarian phenotypes of these patients.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

The Institutional Ethic Committees of the IRCCS San Matteo Hospital and IRCCS Istituto Auxologico Italiano approved the study. All participants gave their written informed consent to the study and to the sampling of their tissues.

Patients {#s2b}
--------

Forty patients with TS were recruited at the Paediatric Department of the University of Pavia, in San Matteo Hospital. All the patients had been diagnosed with TS at birth or during the early infancy on the basis of the conventional karyotyping of at least 30 metaphases from cultured peripheral blood lymphocytes.

The patients were classified according to the presence of the spontaneous menarche (SM) and to the results of the conventional karyotyping (Table [I](#DET436TB1){ref-type="table"}). Six of the 40 patients (15%) experienced SM with FSH and LH values at menarche within the normal range. The clinical data of SM patients are summarized in Table [II](#DET436TB2){ref-type="table"} (ovarian phenotype) and [Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1) (extra-ovarian phenotype). The mean age of the SM patients was 18.8 ± 6.7 years (median: 16.5 years). SM occurred at 11.9--14.4 years (mean: 13.1 ± 1.0 years; median: 13 years). One older patient with SM (SM1) underwent secondary amenorrhoea at 18.6 years and was then put on hormone replacement therapy (Table [II](#DET436TB2){ref-type="table"}). The only other TS feature shown by SM1 was short stature ([Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1)). The other 34 patients (\>12 years of age; median 18.3 years) had hormone levels in the post-menopausal range on at least two independent determinations (FSH \>30 U/l, data not shown) and were classified as primary amenorrhoea (PA). Table IDistribution of the cohort of Turner syndrome patients on the basis of conventional karyotype and pubertal development.Conventional karyotypeTS full cohortComplete spontaneous puberty*n* (%)*n* (%)X-monosomy31 (77.5)2 (33)X-mosaicism with structural abnormalities of the second X3 (7.5)0 (0)X-mosaicism without structural abnormalities of the second X5 (12.5)4 (67)Structural abnormalities of the second X1 (2.5)0 (0)Total40 (100)6 (100) Table IIDetailed hormone dosages at menarche and next follow-up in the six patients with spontaneous pubertal development.PatientAge (years; months)Standard karyotypeMenarche (years; months)Secondary amenorrhoea (years; months)FSH (UI/l)LH (UI/l)E2 (pg/ml)FSH (UI/l)LH (UI/l)E2 (pg/ml)At menarcheAt last follow-upSM1^a^32; 845,X14; 518; 27.41.414132^b^40^b^16^b^SM218; 345,X12; 11--1.74.72344.32.984.6SM315; 945,X/46,XX12; 4--4.93.276.35.82.7114SM419; 945,X/46,XX14; 1--6.13.855.47.11.164.2SM515; 245,X/46,XX13; 1--4.44.861.13.26.180SM615; 145,X/46,XX11; 11--9.83.73062.924.8[^2][^3][^4]

Array-CGH analysis {#s2c}
------------------

All cases underwent aCGH analysis. Genomic DNA (gDNA) was extracted from the whole blood using the GenElute^TM^ Blood Genomic DNA kit (Sigma-Aldrich, St. Louis, MO, USA) in accordance with the manufacturer\'s instructions. Pooled DNA from the peripheral blood of 10 healthy donors (Promega, Southampton, UK), sex-mismatched to the samples, was used as a reference. The genome scan was performed using the Human Genome CGH Microarray Kit 244 K (Agilent Technologies, Santa Clara, CA, USA) which consists of ∼236 000 60-mer oligonucleotide probes covering the entire genome at an average spatial resolution of ∼30 kb. Briefly, 3 µg of DNA from the test and the normal reference samples were processed following the manufacturer\'s protocol. Dye emission was captured by means of a dual-laser scanner. The images were extracted using the Agilent Feature Extraction 9.1 software, and analysed using the DNA Analytics 4.0 software.

A log ratio plot between the test and reference gDNA was assigned so that any aberrations in the copy number of the test DNA at a particular locus were identified as deviations from a modal value of 0 by the ADM-2 algorithm. CNV classification was performed according to the Database of Genomic Variants (<http://projects.tcag.ca/variation/>): a CNV was defined as 'rare' or 'common' if never or previously reported in control subjects, respectively.

The X chromosome mosaic condition was detected qualitatively evaluating, through a mosaicism artificial scale, the vertical right shift of the log ratio profile from the expected value of 0 (Ratio (R): X chromosome copy number of test DNA/X chromosome copy number of reference DNA = 1) towards +1 (*R* = 2) or +1.58 (*R* = 3), the latter due to the isochromosome Xq which involves the presence of three copies of the same chromosome region rather than two. The artificial mosaicism scale was created by mixing the blood samples of one normal diploid male with one normal diploid female, as previously described ([@DET436C3]). The DNA of the artificial mosaicism representing 75, 50, 30 and 10% of 46,XX cell line was used in aCGH experiments, and the obtained log ratio profile shifts were compared with the aCGH results of all TS patients by overlapping every TS X chromosome array profile to the artificial scale, thus giving an estimation of the patient mosaicism level ([Supplementary data, Fig. S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1)). The mosaicism detection limit of this technique was therefore set at 10%.

FISH analysis {#s2d}
-------------

The RPCI-11 BAC clone CTD-2004N6, covering the entire *BMP15* gene at Xp11.22, was selected according to the UCSC Genome Browser (<http://genome.cse.ucsc.edu>, hg19, February 2009) and provided by Invitrogen Ltd (Paisley, UK). The probe was labelled by nick translation with Cy3 (Amersham Biosciences, Chalfont St. Giles, UK) and its physical position was verified on a few female control metaphases derived from peripheral blood lymphocytes.

Multi-colour iFISH analysis was performed in a subset of 13 TS patients (6 SM + 7 PA). For each patient, 300 nuclei derived from PHA-stimulated peripheral blood lymphocytes cultivated for 72 h were analysed by using the CEPX, CEPY, CEP18-Aneuvysion kit (Abbott-Vysis, Chicago, IL, USA), according to the manufacturer\'s instructions. In addition, a few metaphases were analysed to check the structure of the second X chromosome in the euploid cell line. Furthermore, in patient SM1 dual-colour FISH analysis was performed by using the BAC probe specific for *BMP15* in combination with the commercially available centromeric specific probe CEP6 (locus D6Z1) (Abbott-Vysis). In both cases, the combined hybridizations allowed the G1 and G2 cells to be distinguished. In addition, in patient PA4 the presence of a possible mosaic subtelomeric Xp deletion was verified by performing multi-colour FISH analysis using the Vysis ToTelVysion Multi-Color FISH Probe Kit-Mixture 1, which includes the probes TelVysion 1p, TelVysion 1q, TelVysion Xp/Yp and CEP X (Abbott-Vysis). The FISH protocols of [@DET436C22] and [@DET436C21] were followed, with minor modifications.

For iFISH analysis on buccal mucosal cells, the subjects were asked to rinse their mouth twice with drinking water. The surface cells were then scraped from the buccal mucosa of both right and left cheek of each individual by using a cytobrush. The cells were removed from the cytobrush by agitation in ice-cold 70% ethanol. After the transport to the laboratory, the cell suspension was centrifuged at 1200 rpm for 10 min and the supernatant was discarded. The pellet was resuspended in fresh 70% ethanol and dropped across a clean slide. The slides were fixed in fixative (1:1 methanol:acetic acid) for 10 min and then air dried. The slides were checked with a phase microscope for the presence of cells with adequate morphology. Multi-colour iFISH analysis was performed on 300 buccal cells as described above, and the FISH protocol of [@DET436C36] was followed, with minor modifications.

Real-time quantitative PCR {#s2e}
--------------------------

For copy number quantification using real-time quantitative PCR, gDNAs previously extracted from whole blood were analysed for 13 TS patients of the cohort (6 SM and 7 PA). gDNAs were also extracted from buccal epithelium of a subgroup of patients (SM1, SM2, SM3 and PA4) and from vaginal epithelium of SM1, using Oragene DNA Self-Collection Kit (DNA Genotek, Kanata, Ontario, Canada). As controls, gDNAs from 46,XX females, who did not bear CNVs in the regions of interest, and from a 46,XY male were obtained. gDNAs were then used as target templates for the TaqMan Copy Number Assay (Life Technologies, Carlsbad, CA, USA), according to the manufacturer\'s instructions. The target TaqMan Copy Number mixes were chosen to detect: exon 8 (Hs01858886_cn) of the *GYG2* gene (MIM \*300198, at Xp22.3); exon 1 (Hs01299108_cn) and exon 2 (HS00957878_cn) of the *BMP15* gene (MIM \*300247, at Xp11.22); exon 10 (Hs05613398_cn) of the *SMARCA1* gene (MIM \*300012, at Xq26.1); exon 2 (Hs02373345_cn) and exon 7 (Hs01648393_cn) of the *PAPPA* gene (MIM \*176385, at 9q33.1); intron 2 (Hs03902365) and exon 21 (Hs03005502_cn) of the *PDE8A* gene (MIM \*602972, at 15q25.3); and exon 9 (Hs02909158_cn) of the *PRKX* gene (MIM \*300083, at Xp22.33). The RNase P probe targeting the Ribonuclease P RNA component H1 gene (*RPPH1*, MIM \*608513) on chromosome 14q11.2 was chosen as reference probe. Reactions were run on a 7900HT Real-Time PCR instrument (Life Technologies), SDS Software v2.3, performing the Absolute Quantitation method. Four replicates for each sample were analysed to generate reliable copy number calls. After amplification, data files containing the sample replicate CT values for each reporter dye were imported into the CopyCaller software analysis tool (Life Technologies) to calculate sample copy number values by relative quantification, using the comparative CT (ΔΔCT) method. The method measured the CT difference (ΔCT) between target and reference sequences and then compared the ΔCT values of each sample to the ΔCT of calibrator samples (normal 46,XX females), known to have two copies of the target sequence. Each assay was repeated at least twice.

Automated sequencing {#s2f}
--------------------

The entire coding sequence and intron--exon junctions of the *BMP15* gene (GenBank numbers AF082349.1 and AF082350.1) were analysed in patient SM1 by denaturing high-performance liquid chromatography (DHPLC) of PCR-amplified fragments on the WAVE apparatus automatic instrument (Transgenomics, Omaha, NE, USA), as previously described ([@DET436C38]).

Statistical analysis {#s2g}
--------------------

Fisher\'s exact probability test was used to determine whether the prevalence of mosaic karyotypes was significantly different between groups of patients with SM or PA as well as whether the prevalence of the identified autosomal 'common' CNVs was significantly different between TS patients with PA and a control group of 55 healthy women, who presented a normal spontaneous pubertal development and have successfully reproduced. A significance test assigns a *P*-value equal to or smaller than 5%.

Results {#s3}
=======

High-resolution a-CGH analysis detects rare copy number variants in X-linked and autosomal genes relevant to ovarian function {#s3a}
-----------------------------------------------------------------------------------------------------------------------------

Through high-resolution aCGH analysis on 40 TS patients, one X-linked and 16 autosomic heterozygous CNVs were identified (Table [III](#DET436TB3){ref-type="table"}).All of these CNVs affect genes with a known or a possible role in female fertility. Of the 17 CNVs, 3 were rare and involved the *PAPPA, PDE8A* and *BMP15* genes (Fig. [1](#DET436F1){ref-type="fig"}A--C). In addition, in patient PA4, a rare mosaic deletion of at least 2 Mb (chrX:2700316-4739185, hg19) at Xp22.33-p22.32 was detected (Fig. [1](#DET436F1){ref-type="fig"}D), thus revealing the presence of a structural abnormality of the second X chromosome not previously identified by conventional cytogenetic analysis. In order to investigate a possible association between the lack of pubertal development in TS patients and the identified 14 autosomal 'common' CNVs, we performed a case--control genetic association study comparing the frequency of the common CNVs in the PA group (34 individuals) with that found in a group of 55 healthy women with normal puberty. None of these CNVs were significantly enriched in PA TS in comparison with the control population (data not shown). Table IIIDetailed list of the identified CNVs affecting genes potentially related to female fertility.CNV^a^Physical position^b^Chromosomal bandSize (kb)Genes included in the CNV^c^Patient IDRare Losschr9:118971743-1191875389q33.1216***PAPPA***, *ASTN2*PA5 Gainchr15:85591615-8566630915q25.375***PDE8A***^d^PA4 GainchrX:50400649-50955142Xp11.22554***BMP15***, *SHROOM4*SM1Common Gainchr3:100347505-1004196243q12.272***GPR128***^e^SM3 Gainchr3:100380047-1004196243q12.240***GPR128***^e^PA7 Gainchr5:69711984-703145825q13.2603*SERF1A*, *SMN2*, ***NAIP***^e^PA26 Gainchr5:69705562-705870185q13.2881*SERF1A*, *SMN2*, ***NAIP***, *GTF2H2*PA37 Losschr5:69705562-703098555q13.2604*SERF1A*, *SMN2*, ***NAIP***PA40 Losschr6:266079-3079986p25.342***DUSP***SM3 Losschr6:259528-2934936p25.334***DUSP***PA17 Losschr6:283968-3759496p25.392***DUSP***PA31 Gainchr6:259528-3176796p25.358***DUSP***^e^PA33 Gainchr6:259528-2934936p25.334***DUSP***^e^PA34 Losschr8:15952011-160154548p2263***MSR1***PA41 Losschr22:39359112-3938548522q13.126***APOBEC3A***, ***APOBEC3B***SM5 Losschr22:39359112-3938548522q13.126***APOBEC3A***, ***APOBEC3B***PA18 Losschr22:39359112-3938548522q13.126***APOBEC3A***, ***APOBEC3B***PA38[^5][^6][^7][^8][^9] Figure 1Detection of copy number variations. High-resolution aCGH analysis 244 K Agilent identified in patient PA5 a deletion of at least 216 kb at 9q33.1 (chr9:118971743-119187538, hg19), which interrupts the *PAPPA* gene coding region (**A**), in patient PA4 a duplication of at least 75 kb at 15q25.3 (chr15:85591615-85666309, hg19), which includes part of the *PDE8A* gene coding region (**B**), and in patient SM1 a duplication of at least 554 kb at Xp11.22 (chrX:50400649-50955142, hg19,), which contains the entire *BMP15* gene (**C**). In addition, a mosaic deletion of at least 2 Mb at Xp22.33-p22.32 (chrX:2700316-4739185, hg19), which includes the entire *PRKX* gene, was detected in patient PA4 (**D**). The most important genes involved in the identified microrearrangements are highlighted in light blue.

To clarify the structural characteristics of the *BMP15* duplication in patient SM1 (Fig. [1](#DET436F1){ref-type="fig"}C), a specific FISH analysis was performed. A duplicated signal was observed in all the analysed cells (*n* = 100), thus underlying the presence of a tandem duplication (Fig. [2](#DET436F2){ref-type="fig"}A). Interestingly, an additional single signal was found in a few nuclei and metaphases (9%), due to the presence of an euploid cell line, which was characterized by a ring(X) chromosome in addition to the conserved one (Fig. [2](#DET436F2){ref-type="fig"}A and B). A wild-type coding sequence of *BMP15* was detected in SM1. Figure 2Validation and structural characterization of the identified CNVs. (**A**) iFISH analysis performed on 100 nuclei from patient SM1 characterized the rearrangement involving *BMP15* earlier identified by array-CGH analysis as a tandem duplication (thin arrow). In the 9% of the cells an additional smaller signal was identified (big arrow) which represents the low-level mosaic euploid cell line carrying a ring(X) chromosome as seen in the patient\'s metaphases (**B)**. The BAC probe CTD-2004N6, specific for *BMP15*, is shown in red and the CEP6 probe (locus D6Z1) is in green. (**C** and **D**) Multi-colour FISH analysis on metaphases from patient PA4 identified both the 45,X (C) and the 46,XX (D) cell lineages, and confirmed the presence of a heterozygous Xp terminal deletion in the euploid cell lineage (D), as demonstrated by the loss of the expected subtelomeric Xp signal (arrowhead) compared with the conserved X chromosome (arrow). The TelVysion 1p probe is shown in green, the TelVysion 1q is in red, the TelVysion Xp/Yp is in yellow (red + green merged) and CEPX (locus DXZ1) is in blue. (**E**) Real-time quantitative PCR on gDNAs from patients PA4 and PA5. PA4\'s copy number (CN) profile for both the *PRKX* and *GYG2* genes, located at Xp22.32, showed only one copy of both genes (predicted CN = 1n), and confirmed the heterozygous duplication of part of the *PDE8A* gene, located at 15q25.3, by comparing the regions within (dark orange bar, 3n) and outside the duplication (light orange bar, 2n). The CN profile of patient PN5 identified the heterozygous deletion interrupting the *PAPPA* gene, located at 9q33.1, by comparing the region not affected (light purple bar, 2n) with the deleted one (dark purple bar, 1n). All samples were also compared with 46,XX control (calibrator) gDNA. \*The CN profile of the interested regions has been previously tested by array-CGH analysis. Calculated mean CNs are shown on the left-axis, while predicted CNs are displayed on the top of each bar. SD, standard deviation, is represented by the error bars (CN means of the calibrator have been calculated as 2n by the analysis software and therefore no SD values are shown).

The presence of a terminal deletion in the euploid cell line of patient PA4 (Fig. [1](#DET436F1){ref-type="fig"}D) was confirmed by multi-colour FISH analysis, using a probe specific for the chromosome Xp subtelomeric region (Fig. [2](#DET436F2){ref-type="fig"}C and D), and by real-time quantitative PCR, using specific Taqman probes for the *GYG2* and *PRKX* genes (Fig. [2](#DET436F2){ref-type="fig"}E), which revealed one copy of both genes compared with a 46,XX control. Similarly, we could also confirm the rare duplication of part of the *PDE8A* gene in PA4 (Figs [1](#DET436F1){ref-type="fig"}B and [2](#DET436F2){ref-type="fig"}E), and the rare deletion interrupting the *PAPPA* gene in PA5 (Figs [1](#DET436F1){ref-type="fig"}A and [2](#DET436F2){ref-type="fig"}E).

The mosaicism level influences the occurrence of SM in TS {#s3b}
---------------------------------------------------------

On the basis of the conventional cytogenetic results, the frequency of mosaicism in our cohort was significantly higher in the group of patients with pubertal development than in those with PA (67 versus 12%, *P* \< 0.01) (Table [I](#DET436TB1){ref-type="table"}). The X chromosome mosaic condition was confirmed by the aCGH analysis on peripheral blood cells using the mosaicism artificial scale ([Supplementary data, Fig. S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1), Table [IV](#DET436TB4){ref-type="table"}). We demonstrated that all SM patients, including SM1 and SM2, earlier reported as 45,X, showed an appreciable shift of the X chromosome log ratio profile compared with only 4 out of 34 PA patients (Table [IV](#DET436TB4){ref-type="table"}). All SM patients except SM1 were found to be carriers of 45,X/46,XX mosaics ≥10% (Table [IV](#DET436TB4){ref-type="table"}). Of note, in SM1 the profile shift was limited to the region Xp22.1--Xq26.2, thus clarifying the structure of the mosaic ring(X) chromosome, which was previously identified by iFISH analysis (Figs [1](#DET436F1){ref-type="fig"}C, [2](#DET436F2){ref-type="fig"}B and [Supplementary data, Fig. S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1), Table [IV](#DET436TB4){ref-type="table"}). Otherwise, the four cytogenetically ascertained mosaic patients of the PA group showed mosaicism levels \>10%, but invariably contained abnormalities of the second X chromosome (Table [IV](#DET436TB4){ref-type="table"}). Table IVDetailed molecular and molecular-cytogenetic results.Patientquantitative real-time PCRaCGHiFISH^b^Conventional karyotyping^c^*BMP15* at Xp11.22*GYG2* at Xp22.33*SMARCA1* at Xq25X chromosome profile shift, % of mosaicism*CEPX* at Xp11.1-q11pbbmvmpbbmvmpbbmvmpbpblcbmpblc**SM**SM1^a^2n2n2nnnnnnn+, \<10% r(X)(p22.1q26.2)ss\[91\]/ds\[9\]NP\*45,XSM2nnNP\*nnNP\*nnNP\*+, 10%ss\[93.2\]/ds\[6.8\]ss\[90.7\]/ds\[9.3\]45,XSM3nnNP\*nnNP\*nnNP\*+, 10%ss\[82\]/ds\[18\]ss\[80\]/ds\[20\]45,X/46,XXSM42nNP\*NP\*2nNP\*NP\*2nNP\*NP\*+, 30%ss\[26\]/ds\[74\]NP\*45,X/46,XXSM52nNP\*NP\*2nNP\*NP\*2nNP\*NP\*+, 75%ss\[19\]/ds\[81\]NP\*45,X/46,XXSM62nNP\*NP\*2nNP\*NP\*2nNP\*NP\*+, 75%ss\[19\]/ds\[81\]NP\*45,X/46,XX**PA**PA1nNP\*NP\*nNP\*NP\*nNP\*NP\*Absentss\[99\]/ds\[1\]NP\*45,XPA2nNP\*NP\*nNP\*NP\*nNP\*NP\*Absentss\[99.4\]/ds\[0.6\]NP\*45,XPA3nNP\*NP\*nNP\*NP\*nNP\*NP\*Absentss\[99\]/ds\[1\]NP\*45,XPA4n2nNP\*nnNP\*n2nNP\*+, 10-30% del(X)(p22.33→p22.32)ss\[63.7\]/ds\[36.3\]ss\[36\]/ds\[64\]45,X/46,XXPA5nNP\*NP\*nNP\*NP\*3nNP\*NP\*− (Xp) + (Xq), % NAss\[15\]/ds\[85\]NP\*45,X/46,X,i(Xq)PA6nNP\*NP\*nNP\*NP\*3nNP\*NP\*− (Xp) + (Xq), % NAss\[23\]/ds\[77\]NP\*45,X/46,X,i(Xq)PA7nNP\*NP\*nNP\*NP\*nNP\*NP\*− (Xp) + (Xq), % NAss\[85\]/ds\[15\]NP45,X/46,X,i(Xq)PA8-PA40NP NPNPNPNPNPNPNPNPAbsentNPNP45,X[^10][^11][^12][^13]

The mosaicism rates were then evaluated by multi-colour iFISH analysis and real-time quantitative PCR on peripheral blood. These two approaches were performed on a subgroup of 13 patients, SM1-6 and PA1-7, including the only 4 patients with PA who were mosaics at aCGH analysis (PA4-7) and 3 representative cases with absent mosaicism signals (Table [IV](#DET436TB4){ref-type="table"}). The iFISH analysis revealed a mosaic condition in PHA-stimulated cultures of all SM and PA patients, based on the presence of one or two signals specific for the X chromosome centromeric α-sat DNA (locus DxZ1) (Fig. [3](#DET436F3){ref-type="fig"}A), even if at a very low degree (≤1%) in the three 45,X patients PA with absent X chromosome shift at aCGH (Table [IV](#DET436TB4){ref-type="table"}). The same approach was carried out on the buccal mucosa of SM2, SM3 and PA4. The mosaicism rate found in peripheral blood was confirmed in buccal mucosa cells of SM2 and SM3, whereas a double amount of the euploid cell line was identified in PA4 (Table [IV](#DET436TB4){ref-type="table"}, Fig. [3](#DET436F3){ref-type="fig"}B). Figure 3X chromosome mosaicism evaluation. In patient PA4, the euploid cell line mosaic condition was established by iFISH analysis both in peripheral blood lymphocyte culture (**A**) and in buccal mucosa (**B**) where a double amount of 46,XX cells was identified. The CEPX probe (locus DXZ1) is shown in green and the CEP18 (locus D18Z1) is in blue. (**C**--**F**) Mosaicism levels in SM patients (pink bars on the left) and PA patients (green-light blue bars on the right) were evaluated by real-time quantitative PCR in peripheral blood (pb), buccal (bm) and vaginal (vm) mucosa, depending on tissues availability. SM1, harbouring the *BMP15* duplication, SM4, SM5 and SM6 all showed two copies of *BMP15* (D and E). Two copies of *GYG2* and *SMARCA1* genes were identified in SM4, SM5 and SM6 (C and F) who have mosaicism levels ≥30% (sensitivity cut-off of the method), whereas SM1, SM2 and SM3 showed only one copy of *GYG2* and *SMARCA1* (mosaicism level \<10%) (C and F). SM1\'s copy number profile was confirmed also in bm and vm. PA1-7 showed one copy of *BMP15*, *GYG2* and *SMARCA1* genes (C and F), except for PA5 and PA6 who presented with more than two copies of *SMARCA1* (3n) because of the isochromosome(Xq) in \>30% of the euploid cell line (F). In PA4\'s bm, real-time quantitative PCR confirmed the increased copy number mosaic levels for *BMP15* and *SMARCA1* (2n) and the mosaic deletion at Xp22.33-p22.32 including *GYG2*. All samples were also compared with 46,XX (calibrator) and 46,XY control gDNAs. Calculated mean CNs are shown on the left-axis, while predicted CNs are displayed on the top of each bar. SD, standard deviation, is represented by the error bars (CN means of controls have been calculated 2n by the analysis software and therefore no SD values are shown).

A mean of two copies of *GYG2*, *BMP15* and *SMARCA1* genes, which are located at chromosome Xp22.3, Xp11.22 and Xq25, respectively, were identified by real-time quantitative PCR in the only the three patients with a mosaicism level ≥30% (SM4-6), thus establishing a sensitivity threshold of around 30% for the mosaicism detection by means of this technique (Table [IV](#DET436TB4){ref-type="table"}, Fig. [3](#DET436F3){ref-type="fig"}C--F). As expected, two copies of *BMP15* were also detected in SM1 (Table [IV](#DET436TB4){ref-type="table"}, Fig. [3](#DET436F3){ref-type="fig"}D and E). All the seven PA patients showed one copy of the three analysed genes, except for PA5 and PA6 who presented with more than two copies of *SMARCA1* because of a duplication of the only Xq arm in \>30% of the cells (Table [IV](#DET436TB4){ref-type="table"}, Fig. [3](#DET436F3){ref-type="fig"}C--F). For SM1-3 and PA4, this analysis could be further extended to another tissue of different embryonic origin, such as buccal epithelium or vaginal epithelium, confirming the same blood copy number profile for *BMP15*, *GYG2* and *SMARCA1*, except for PA4 who showed an increment only in *BMP15* and *SMARCA1* copy numbers (Table [IV](#DET436TB4){ref-type="table"}, Fig. [3](#DET436F3){ref-type="fig"}C--F).

Discussion {#s4}
==========

In the present work, we have analysed by different molecular and molecular-cytogenetic approaches a series of 40 TS patients, 6 of them with a spontaneous pubertal development. The results of this pilot study suggest that a mosaicism \<10% for the euploid cell lineage, as measured by modern molecular-cytogenetic techniques on uncultivated tissues, may predict the lack of future pubertal development. When confirmed on larger cohorts, this approach may become a useful complement to the previously proposed biochemical markers ([@DET436C9]; [@DET436C2]; [@DET436C16]). The whole of our data, including those collected on tissues of different embryological origins (peripheral blood, buccal and vaginal mucosa) in a subgroup of TS patients, are consistent with (i) the advanced hypothesis that all TS patients bear some degree of mosaicism ([@DET436C15]; [@DET436C35]) and (ii) the positive correlation between the TS mosaic karyotype and the probability of a spontaneous pubertal onset ([@DET436C29]). Indeed, mosaicism-like signals were detected by aCGH in four PA patients, but the additional studies confirmed the presence of mosaicisms with cells harbouring abnormalities of the second X chromosome.

Therefore, aCGH represents a valuable alternative method for TS diagnosis, as recently proposed for SNP array ([@DET436C33]). The aCGH could indeed detect structural abnormalities of the second X in the euploid cell lines, which were not identified by standard karyotype, and precisely maps the breakpoints, as seen in SM1 and PA4 (Table [IV](#DET436TB4){ref-type="table"}, Fig. [1](#DET436F1){ref-type="fig"}C and D). By avoiding the growth bias in favour of the euploid cell line during *in vitro* culture, aCGH was able to detect the presence of the euploid cell lineages at low mosaic levels (around 10%) in two SM patients, both previously karyotyped as 45,X (Tables [I](#DET436TB1){ref-type="table"} and [IV](#DET436TB4){ref-type="table"}). Of note, the use of combined molecular-cytogenetic approaches in different tissues would be of help also in unveiling cryptic 45,X/46,XY mosaics. Nevertheless, in contrast with the SNP array, a quantitative estimation of X chromosome mosaicism rate cannot be performed directly by analysing the aCGH profile shift and an *ad hoc* mosaicism scale must be applied ([Supplementary data, Fig. S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1)).

The patients SM1 and PA4 represent two cases apparently in contrast with the '10% mosaicism threshold'. The autosomic or X-linked CNVs identified in these cases involve genes related to ovarian function, and may thus contribute to explain the discrepancy between the karyotype and the ovarian phenotype (Table [IV](#DET436TB4){ref-type="table"}). In SM1, the aCGH analysis identified a duplication at Xp11.22 containing the entire sequence of the only *BMP15* gene. *BMP15* (MIM \*300247) is located within the Xp locus associated with premature ovarian failure (POF) and encodes an oocyte-derived growth factor of the TGF-β superfamily, involved in follicular development as a critical regulator of many granulosa cells processes and ovulation rate ([@DET436C25]; [@DET436C32]). Evidence of the fundamental role of this factor in follicular development came from animal models (rodents and sheeps) and humans ([@DET436C7]; [@DET436C10]; [@DET436C6]; [@DET436C14]). Several mutational screenings performed in different cohorts of patients affected with 46,XX Primary Ovarian Insufficiency described the significant association with loss-of-function variations in *BMP15* ([@DET436C32]), and functional analysis of some of the reported variants were consistent with a mechanism of haploinsufficiency ([@DET436C38]; [@DET436C31]; [@DET436C47]). More recently, a deletion of about 4 Mb at Xp11.23-p11.22, including the entire *BMP15* gene, has been identified in a POF patient by SNP array analysis ([@DET436C24]). As a double dose of BMP15 seems to be required for the normal rate of follicular depletion in 46,XX women and to provide an adequate anti-apoptotic effect on granulosa cells ([@DET436C31]), our data are consistent with the hypothesis that a *BMP15* duplication on the conserved X chromosome might have preserved the adequate gene dosage in the developing ovary of SM1, thus leading to the conservation of a certain amount of functional follicles at pubertal age and the ability to compensate for the presence of a cell line with r(X)(p22.1q26.2). Indeed, such a structural abnormality generates the complete monosomy of the Xpter-Xp22.1 and Xq26.2-Xqter regions (Fig. [1](#DET436F1){ref-type="fig"}C), which would be expected to be less stable compared with a cell line with a non-rearranged chromosome X (i.e. SM2) (Table [IV](#DET436TB4){ref-type="table"}). However, SM1 underwent secondary amenorrhoea after 4 years of regular menses (Table [II](#DET436TB2){ref-type="table"}). It is therefore likely that the haploinsufficiency of possible ovarian determinants located in the monosomic regions contributed to the POF, as well as the haploinsufficiency of the *SHOX* gene (MIM \*312865), located at Xp22.3, which is responsible for the patient\'s short stature ([Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/det436/-/DC1)). In the other patients with SM, it is reasonable that a correct dosage of several X-linked candidate factors, including BMP15, likely due to a sufficient amount of the euploid cell line in the ovary, can sustain the ovarian development and the folliculogenesis at least for some years, delaying a complete ovarian insufficiency.

The major role of different loci at Xp rather than at Xq for the ovarian phenotype may be strengthened by the PA5-7 cases who have one copy of *BMP15* and Xq trisomy due to an isochromosome (Xq) in the euploid cell line (Table [IV](#DET436TB4){ref-type="table"}). Accordingly, [@DET436C13] described spontaneous puberty in only 1 out of 7 TS patients with a 45,X/46,X,i(Xq) karyotype. Interestingly, PA5 carries a heterozygous partial deletion of the *PAPPA* gene, which could play an additional deleterious role on ovarian phenotype (Figs [1](#DET436F1){ref-type="fig"}A and [2](#DET436F2){ref-type="fig"}E). Indeed, the involvement of PAPPA, the pregnancy-associated plasma protein-A, in modulating ovarian function by control of the bioavailability of ovarian insulin-like growth factor is known ([@DET436C28]) and, recently, it has been demonstrated that the lack of this functional metalloproteinase compromises mouse ovarian steroidogenesis and female fertility ([@DET436C26]).

The second remarkable case was PA4, whose molecular-cytogenetic findings revealed a mosaicism level (in both peripheral blood and buccal mucosa) that was similar to that of SM patients (Table [IV](#DET436TB4){ref-type="table"}). Nevertheless, aCGH analysis identified a structural abnormality of an X chromosome in the 46,XX cell lineage (i.e. a rare mosaic deletion at Xp22.33-p22.32), which might have contributed to the ovarian defect (Figs [1](#DET436F1){ref-type="fig"}D and [2](#DET436F2){ref-type="fig"}C--E). The deleted region, indeed, includes among others the *PRKX* gene which encodes an X-linked cAMP-dependent protein kinase expressed in the ovary, with a possible role in renal epithelial morphogenesis and in macrophage and granulocyte maturation ([@DET436C49]). Although a correlation between this protein and female fertility has never been reported, a microduplication affecting the only *PRKX* gene has previously been reported in a patient with POF (menarche at age 14 years and menopause at age 37 years) ([@DET436C8]). Furthermore, bioinformatic analysis of PRKX predicted functional partners (the progesterone receptor, the androgen receptor and different members of adenylate ciclase family) supports its role in female meiosis as these proteins are known to be involved in the fine regulation of oocyte maturation ([@DET436C42]; [@DET436C11]; [@DET436C17]). In addition, PA4 was a carrier of an autosomal microduplication, affecting the *PDE8A* gene coding region and potentially resulting in *PDE8A* haploinsufficiency (Figs [1](#DET436F1){ref-type="fig"}B and [2](#DET436F2){ref-type="fig"}E). *PDE8A* encodes a cAMP-phosphodiesterase, an enzyme that catalysis the transformation of cyclic nucleotides into 5′ nucleotides, whose functional presence in the bovine ovarian follicle has recently been demonstrated ([@DET436C40]).

These data would support the idea that defects in autosomal loci may contribute to the ovarian phenotype of TS patients in addition to the haploinsufficiency of X-linked genes ([@DET436C30]), as previously reported in a few series of patients with POI ([@DET436C1]; [@DET436C19]; [@DET436C20]; [@DET436C24]).

Considering the autosomal 'common' CNVs identified in our cohort (Table [III](#DET436TB3){ref-type="table"}), the two involving the *NAIP* and *DUSP22* genes have recently been proposed as candidates for POF ([@DET436C1]). Indeed, *NAIP* encodes the neuronal apoptosis inhibitory protein and is overexpressed in breast cancer patients with unfavourable clinical features ([@DET436C5]), whereas *DUSP22*, the dual specificity phosphatases gene, is involved in the regulation of estrogen receptor α-mediated signalling ([@DET436C41]). Here, the association of the ovarian defect with both *NAIP* and *DUSP22* CNVs failed to be statistically significant in the case--control analysis, although a *P*-value of 0.06 has been assigned to *DUSP22* gains. The other relevant CNVs were selected because of their high expression level in the ovary (e.g. the *GPR128* gene encoding a G protein-coupled receptor, and the *MSR1* gene coding for a Macrophage Scavenger Receptor) or because of a likely involvement in ovarian function (e.g. the cluster of *APOBEC* genes coding for the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3) (see the following reviews: [@DET436C48]; [@DET436C4]; [@DET436C46]; [@DET436C18]; [@DET436C45]). Although these CNVs are currently considered as benign variants, and the affected genes cannot be considered as susceptibility loci for ovarian failure in TS, we cannot rule out that their presence, individually or in combination with other abnormalities, may have contributed to the premature ovarian failure in the corresponding TS patients.

In conclusion, the present work supports gene dosage as a relevant mechanism contributing to the ovarian phenotype of TS patients. However, definitive confirmation of the reported findings should be obtained by an extensive CNV structural characterization and expression studies of candidate genes in animal models. Further studies on large TS cohorts are needed to elucidate the burden of X-linked dosage-sensitive genes in spontaneous pubertal development. These should evaluate the X chromosome mosaicism rates in tissues of different embryonic origin, including the ovary. The first duplication rearrangement of *BMP15* in a 45,X TS patient with SM brings additional evidence for a prominent determinant role of this Xp-linked gene on ovarian folliculogenesis. The detection of CNVs in autosomal ovary-related genes may generate further insights on the fundamental mechanisms contributing to ovarian function.
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[^1]: The authors consider that the first two authors should be regarded as joint first authors.

[^2]: ^a^After secondary amenorrhoea, SM1 was put on hormone replacement therapy.

[^3]: ^b^Before replacement therapy.

[^4]: E2, 17 β-estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

[^5]: ^a^Copy number variations classification has been performed according to the Database of Genomic Variants (<http://projects.tcag.ca/variation/>).

[^6]: ^b^According to the genome assembly hg19 (UCSC Genome Browser, release February 2009, <http://genome.cse.ucsc.edu>, hg19).

[^7]: ^c^Genes likely to be implicated in female fertility are indicated in bold.

[^8]: ^d^Intragenic duplication likely perturbing gene expression.

[^9]: ^e^Partial gene duplications involving either 5' or 3' end must be further molecularly characterized to clarify the actual perturbation of gene expression.

[^10]: ^a^The patient has a *BMP15* wild-type sequence.

[^11]: ^b^The euploid cell line was generally estimated by FISH at a higher rate than the expected rate on the basis of the aCGH profile probably due to a selection bias in favour of the euploid cell line during cell culture.

[^12]: ^c^At least 30 metaphases were analysed.

[^13]: bm, buccal mucosa; ds, double signal; n, copy number; NA, not available due to the lack of an artificial mosaicism scale *ad hoc*; NP, not performed; NP\*, not performed due to the lack of proper samples; PA, primary amenorrhoea; pb, peripheral blood; pblc, peripheral blood lymphocytes cultures; SM, spontaneous menarche; ss, single signal; vm, vaginal mucosa; +, present; −, absent.
